Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$57.09
-0.5%
$59.56
$42.52
$62.89
$116.57B0.2612.53 million shs7.43 million shs
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$10.25
$10.25
$1.40
$10.44
$744.95M-0.331.32 million shsN/A
HSBC Holdings plc stock logo
HSBC
HSBC
$87.34
-3.1%
$86.35
$56.21
$94.79
$300.28B0.562.19 million shs2.79 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$986.78
+1.9%
$947.05
$623.78
$1,133.95
$934.36B0.483.19 million shs1.96 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.92
+1.2%
$38.50
$35.12
$81.44
$201.30B0.7722.19 million shs17.20 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.46
+0.6%
$27.17
$21.97
$28.75
$150.77B0.3542.75 million shs44.09 million shs
Synopsys, Inc. stock logo
SNPS
Synopsys
$502.21
+0.9%
$430.07
$376.18
$651.73
$96.40B1.252.05 million shs1.03 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$145.29
+0.4%
$149.39
$127.35
$160.59
$38.14B0.5813.14 million shs5.76 million shs
The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.00%+0.66%-2.23%+4.06%+15.20%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00%0.00%0.00%0.00%0.00%
HSBC Holdings plc stock logo
HSBC
HSBC
0.00%+2.33%+9.03%+3.41%+62.92%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+11.12%+3.13%-3.79%+16.98%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+6.46%+18.75%-12.91%-36.71%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-1.75%-7.12%+2.22%+8.91%
Synopsys, Inc. stock logo
SNPS
Synopsys
0.00%-1.91%+23.51%+16.67%+3.54%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
0.00%+1.18%-1.12%-5.80%+4.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$57.09
-0.5%
$59.56
$42.52
$62.89
$116.57B0.2612.53 million shs7.43 million shs
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$10.25
$10.25
$1.40
$10.44
$744.95M-0.331.32 million shsN/A
HSBC Holdings plc stock logo
HSBC
HSBC
$87.34
-3.1%
$86.35
$56.21
$94.79
$300.28B0.562.19 million shs2.79 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$986.78
+1.9%
$947.05
$623.78
$1,133.95
$934.36B0.483.19 million shs1.96 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.92
+1.2%
$38.50
$35.12
$81.44
$201.30B0.7722.19 million shs17.20 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.46
+0.6%
$27.17
$21.97
$28.75
$150.77B0.3542.75 million shs44.09 million shs
Synopsys, Inc. stock logo
SNPS
Synopsys
$502.21
+0.9%
$430.07
$376.18
$651.73
$96.40B1.252.05 million shs1.03 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$145.29
+0.4%
$149.39
$127.35
$160.59
$38.14B0.5813.14 million shs5.76 million shs
The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.00%+0.66%-2.23%+4.06%+15.20%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00%0.00%0.00%0.00%0.00%
HSBC Holdings plc stock logo
HSBC
HSBC
0.00%+2.33%+9.03%+3.41%+62.92%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+11.12%+3.13%-3.79%+16.98%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+6.46%+18.75%-12.91%-36.71%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-1.75%-7.12%+2.22%+8.91%
Synopsys, Inc. stock logo
SNPS
Synopsys
0.00%-1.91%+23.51%+16.67%+3.54%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
0.00%+1.18%-1.12%-5.80%+4.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.37
Hold$61.317.41% Upside
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00
N/AN/AN/A
HSBC Holdings plc stock logo
HSBC
HSBC
2.70
Moderate Buy$63.00-27.87% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,217.5923.39% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5645.94% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.748.63% Upside
Synopsys, Inc. stock logo
SNPS
Synopsys
2.41
Hold$531.005.73% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.73
Moderate Buy$145.450.11% Upside

Current Analyst Ratings Breakdown

Latest BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
5/1/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingNeutral
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Lower Price TargetBuy$1,294.00 ➝ $1,133.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,205.00 ➝ $1,230.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,260.00 ➝ $1,283.00
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
4/27/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Lower Price TargetOutperform$1,296.00 ➝ $1,058.00
4/22/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
DowngradeHold (C-)Sell (D+)
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.42$7.97 per share7.16$9.09 per share6.28
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$60K12,415.83N/AN/A$2.95 per share3.47
HSBC Holdings plc stock logo
HSBC
HSBC
$66.22B4.53$8.64 per share10.11$59.87 per share1.46
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B14.30$25.75 per share38.32$28.07 per share35.15
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$309.06B0.65$4.80 per share9.36$6.58 per share6.83
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.40$4.42 per share5.99$15.26 per share1.73
Synopsys, Inc. stock logo
SNPS
Synopsys
$7.05B13.64$12.17 per share41.25$152.50 per share3.29
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$3.5616.049.390.1715.01%64.87%13.16%N/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/A
HSBC Holdings plc stock logo
HSBC
HSBC
$22.29B$6.0514.449.420.8916.07%13.10%0.82%5/5/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1535.1323.511.1334.98%105.77%23.76%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$3.4712.9913.3710.4233.03%68.91%22.86%5/6/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3619.509.38N/A12.42%20.48%8.86%5/5/2026 (Estimated)
Synopsys, Inc. stock logo
SNPS
Synopsys
$1.33B$6.4478.1540.933.9913.76%6.83%3.93%5/27/2026 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A21.15N/AN/AN/AN/AN/AN/A

Latest BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2026Q2 2026
Synopsys, Inc. stock logo
SNPS
Synopsys
$3.17N/AN/AN/A$2.25 billionN/A
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87N/AN/AN/A$11.12 billionN/A
5/5/2026Q1 2026
HSBC Holdings plc stock logo
HSBC
HSBC
$2.12$0.44-$1.68$2.00$18.60 billion$19.13 billion
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.71$0.75+$0.04$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.42$1.58+$0.16$1.31$10.93 billion$11.49 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
2/25/2026Q4 2025
HSBC Holdings plc stock logo
HSBC
HSBC
$1.60$1.85+$0.25$1.35$17.01 billion$17.72 billion
2/25/2026Q1 2026
Synopsys, Inc. stock logo
SNPS
Synopsys
$3.56$3.77+$0.21$0.34$2.39 billion$2.41 billion
2/14/2026Q4 2025
HSBC Holdings plc stock logo
HSBC
HSBC
N/A$1.35N/A$1.35N/A$17.70 billion
2/5/2026Q4 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.65$1.26-$0.39$0.53$12.24 billion$12.50 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.524.41%+1.61%70.79%17 Years
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/A
HSBC Holdings plc stock logo
HSBC
HSBC
$8.9810.28%+25.58%148.43%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.70%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.743.87%+21.74%50.14%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.50%-13.20%126.47%16 Years
Synopsys, Inc. stock logo
SNPS
Synopsys
N/AN/AN/AN/AN/A
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.501.72%N/AN/AN/A

Latest BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.42%5/8/20265/8/20266/12/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.72%5/15/20265/15/20266/10/2026
3/2/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.23%4/2/20264/2/20265/1/2026
2/25/2026
HSBC Holdings plc stock logo
HSBC
HSBC
quarterly$2.2511.51%3/13/20263/13/20264/30/2026
1/1/2100
HSBC Holdings plc stock logo
HSBC
HSBC
quarterly$1.558%3/7/20243/8/20244/25/2024
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.10
1.42
1.28
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.02
7.73
7.73
HSBC Holdings plc stock logo
HSBC
HSBC
0.62
0.87
0.87
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.61
0.80
0.57
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.16
0.87
Synopsys, Inc. stock logo
SNPS
Synopsys
0.33
1.36
1.26
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
31472.68 million52.33 millionNo Data
HSBC Holdings plc stock logo
HSBC
HSBC
208,7203.44 billion3.44 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000944.82 million943.50 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.69 billion5.65 billionOptionable
Synopsys, Inc. stock logo
SNPS
Synopsys
28,000191.56 million190.49 millionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A262.11 millionN/ANot Optionable

Recent News About These Companies

Close-up of semiconductor chips and silicon wafer, representing AMD and AI-driven growth in the semiconductor industry.
What Q1 Earnings Could Mean for the S&P 500 Uptrend (XLV)
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$57.08 -0.30 (-0.51%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gracell Biotechnologies stock logo

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

HSBC stock logo

HSBC NYSE:HSBC

$87.34 -2.79 (-3.10%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

HSBC Holdings plc provides banking and financial services worldwide. The company operates through Wealth and Personal Banking, Commercial Banking, and Global Banking and Markets segments. The Wealth and Personal Banking segment offers retail banking and wealth products, including current and savings accounts, mortgages and personal loans, credit and debit cards, and local and international payment services; and wealth management services comprising insurance and investment products, global asset management services, investment management, and private wealth solutions. This segment serves personal banking and high net worth individuals. The Commercial Banking segment provides credit and lending, treasury management, payment, cash management, commercial insurance, and investment services; commercial cards; international trade and receivables finance services; foreign exchange products; capital raising services on debt and equity markets; and advisory services. It serves small and medium sized enterprises, mid-market enterprises, and corporates. The Global Banking and Markets segment offers financing, advisory, and transaction services; and credit, rates, foreign exchange, equities, money markets, and securities services; and engages in principal investment activities. It serves government, corporate and institutional clients, and private investors. HSBC Holdings plc was founded in 1865 and is headquartered in London, the United Kingdom.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$986.78 +18.85 (+1.95%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$44.92 +0.53 (+1.20%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$26.46 +0.16 (+0.59%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Synopsys stock logo

Synopsys NASDAQ:SNPS

$502.21 +4.71 (+0.95%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as optical products, and mechatronic simulations. Further, it provides security and quality testing products, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. Additionally, the company provides intelligent orchestration solution, software risk manager, and black duck software composition analysis tools. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Sunnyvale, California.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$145.29 +0.56 (+0.39%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.